deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT05608005

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

Sponsor: Sanofi Pasteur, a Sanofi Company

Conditions Healthy Volunteers Influenza
Interventions Panblok + MF59 Dose 1 Panblok + MF59 Dose 2 Unadjuvanted Panblok Dose 3
Updated 13 times since 2022 Last updated: Sep 21, 2025 Started: Nov 3, 2022 Primary completion: Feb 18, 2023 Completion: Feb 13, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Healthy Volunteers and Influenza and is currently completed. Sanofi Pasteur, a Sanofi Company leads this study, which shows 13 recorded versions since 2022 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Dec 2022 – ~Mar 2023 · 3 months · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Sep 2023 · 4 months · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Apr 2024 · 5 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 7 months · monthly snapshot

Change History

13 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Mar 2025 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  4. Sep 2024 — Mar 2025 [monthly]

    Completed PHASE1/PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 8 earlier versions

  1. Apr 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed · Phase: PHASE2 → PHASE1_PHASE2

  2. Nov 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Oct 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

  5. May 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE2

  6. Apr 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE2

  7. Mar 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Dec 2022 — Mar 2023 [monthly]

    Recruiting PHASE2

    First recorded

Nov 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sanofi Pasteur, a Sanofi Company
Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anderson, United States , Atlanta, United States , Austin, United States , Chattanooga, United States , Hallandale, United States , Hollywood, United States , Mesa, United States , Metairie, United States , Miami, United States , Pittsburgh, United States and 4 more locations